Why the study?
Does administration of ajmaline induce ventricular tachycardia in a patient with Brugada syndrome?
Does administration of ajmaline induce ventricular tachycardia in a patient with Brugada syndrome?
Administration of Class I antiarrhythmic drugs like ajmaline can have arrhythmogenic potential, inducing sustained monomorphic ventricular tachycardia in patients with Brugada syndrome.
Ajmaline may provoke sustained VT in Brugada syndrome; this case report leaves open questions on drug safety and risk stratification.
We present the case of a 13-year-old boy with an episode of aborted sudden death, absence of structural heart disease, and a characteristic ECG pattern of right bundle branch block with persistent ST-segment elevation in the right precordial leads, in whom a monomorphic sustained ventricular tachycardia developed spontaneously after the administration of ajmaline. This effect may be related to an increased inhomogeneity of repolarization mediated by the drug and demonstrates the arrhythmogenic potential of Class I antiarrhythmic drugs in patients with Brugada syndrome.
No takes yet. Share an insight, caveat, or question.
Bermúdez et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: